54 results
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or arbitral body (public or private … Administration (“TGA”), the Department of Health and Human Services, the European Commission, the European Medicines Agency (“EMA”) or any other Health
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
an exemption. The withholding obligations under FATCA generally apply to dividends on our common stock. The U.S. Department of the Treasury has issued
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
under FATCA generally apply to dividends on our common stock. The U.S. Department of the Treasury has issued proposed Treasury Regulations providing
8-K
EX-10.1
CGTX
Cognition Therapeutics Inc
1 May 23
Departure of Directors or Certain Officers
7:30am
, to the attention of its Legal Department at the address of its principal executive office; or (c) or at such other address as may have been furnished
8-K
EX-10.1
p99wpnhleyo9e8s
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
S-3
EX-1.2
xddt3 nxs1qq
23 Dec 22
Shelf registration
4:16pm
8-K
EX-1.1
9o0mw2w
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
x5zedo
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
nluqc1
20 Oct 22
Draft registration statement
12:00am
10-K
fj1zfd03o
30 Mar 22
Annual report
7:40am
8-K
EX-99.2
iefswj 5ftxjhoio9p9r
15 Mar 22
Regulation FD Disclosure
9:32am
424B4
cft1pe767 strxuhpe
12 Oct 21
Prospectus supplement with pricing info
4:11pm